Soliris

Alexion’s Soliris follow-up Ultomiris snares EU approval
Alexion’s Soliris follow-up Ultomiris snares EU approval
Pharmaforum
Alexion
Europe
Ultomiris
Soliris
patents
PNH
Flag link:
Alexion's cash cow Soliris just got fatter as FDA greenlights another blockbuster indication
Alexion's cash cow Soliris just got fatter as FDA greenlights another blockbuster indication
Endpoints
Alexion
Soliris
FDA
autoimmune disease
NMOSD
Flag link:
FDA Action Alert: Regeneron, Sanofi, Celgene
FDA Action Alert: Regeneron, Sanofi, Celgene
BioSpace
FDA
drug approvals
Acer Therapeutics
Edsivo
Regeneron
Sanofi
Dupixent
Celgene
Revlimid
Alexion
Soliris
Dova Pharmaceuticals
Doptelet
Nabriva Therapeutics
Contepo
Retrophin
Thiola
Flag link:
3 Drug Stocks That Could Win From Key FDA Approvals in June
3 Drug Stocks That Could Win From Key FDA Approvals in June
Motley Fool
Merck
Amag Pharmaceuticals
Alexion Pharma
FDA
Keytruda
Vyleesi
Soliris
Flag link:
Mark Your Calendar For These June PDUFA Dates
Mark Your Calendar For These June PDUFA Dates
Yahoo/Benzinga
FDA
Merck
Zerbaxa
XERIS
Gvoke HypoPen
Keytruda
Amag Pharmaceuticals
Palatin
Vyleesi
Acer Therapeutics
Edsivo
Sanofi
Regeneron
Dupixent
Alexion
Soliris
Retrophin
Thiola
Allergan
Botox
Flag link:
Go or no go? Merck, Regeneron and Alexion await US expansion
Go or no go? Merck, Regeneron and Alexion await US expansion
EP Vantage
Merck
Keytruda
Sanofi
Regeneron
Dupixent
Alexion
Soliris
FDA
Dova Pharmaceuticals
Retrophin
Flag link:
Alexion gets off to the races with key Ultomiris, Soliris launches
Alexion gets off to the races with key Ultomiris, Soliris launches
Fierce Pharma
Alexion
Ultomiris
Soliris
drug launches
Flag link:
14 Drugs Earn Billions for These Massachusetts Biotechs
14 Drugs Earn Billions for These Massachusetts Biotechs
BioSpace
Massachusetts
Boston
Biogen
Tecfidera
Benepali
Shire
Takeda
Vyvanse
Vertex Pharmaceuticals
Orkambi
Kalydeco
Alexion
Soliris
Strensiq
Sanofi Genzyme
Lantus
Ironwood Pharmaceuticals
Linzess
Flag link:
Alexion aims for fourth rare disease use for blockbuster Soliris
Alexion aims for fourth rare disease use for blockbuster Soliris
Pharmaforum
Alexion Pharmaceuticals
Soliris
neuromyelitis optica spectrum disorder
Flag link:
Alexion wins approval for rare disease drug, aims to switch patients from blockbuster Soliris
Alexion wins approval for rare disease drug, aims to switch patients from blockbuster Soliris
Stat
Alexion Pharmaceuticals
FDA
Ultomiris
Soliris
PNH
Flag link:
Ra Pharma files $100M round as Soliris rival clears phase 2 trial
Ra Pharma files $100M round as Soliris rival clears phase 2 trial
Fierce Biotech
Ra Pharma
Soliris
clinical trials
myasthenia gravis
zilucoplan
Flag link:
Alexion’s Soliris wows in rare disease PhIII trial, opening up a new franchise worth $500M-$700M
Alexion’s Soliris wows in rare disease PhIII trial, opening up a new franchise worth $500M-$700M
Endpoints
Alexion
Soliris
clinical trials
NMOSD
Flag link:
How badly does Alexion want its Soliris follow-on? Enough to use a rare fast pass
How badly does Alexion want its Soliris follow-on? Enough to use a rare fast pass
Biopharma Dive
Alexion
Soliris
fast pass
FDA
priority review
ALXN1210
Flag link:
Alexion's follow-on stacks up to Soliris
Alexion's follow-on stacks up to Soliris
Biopharma Dive
Alexion
Soliris
ALXN1210
paroxysmal nocturnal hemoglobinuria
PNH
Flag link:
Alexion turns focus to rebuilding pipeline amid restructuring
Alexion turns focus to rebuilding pipeline amid restructuring
Biopharma Dive
Alexion
restructuring
Soliris
Flag link:
Prepping PhIII for Soliris rival, Apellis rides a boisterous market to a $150M IPO
Prepping PhIII for Soliris rival, Apellis rides a boisterous market to a $150M IPO
Endpoints
Soliris
Apellis
Flag link:
Alexion cutting 600 jobs and moving headquarters in major shakeup
Alexion cutting 600 jobs and moving headquarters in major shakeup
Stat
Alexion
layoffs
Soliris
Flag link:
Alexion bolsters Soliris patent defense
Alexion bolsters Soliris patent defense
BioPharma Dive
Alexion
Soliris
patents
Rare Diseases
Flag link:
Alexion Being Probed by HHS Inspector General; Shares Fall
Alexion Being Probed by HHS Inspector General; Shares Fall
Bloomberg
Alexion Pharmaceuticals
HHS
Soliris
fraud
Flag link:
Top 25 rare disease brands, by sales
Top 25 rare disease brands, by sales
Medical Marketing and Media
rare disease
Copaxone
Teva Pharmaceutical
Avonex
Biogen
Sensipar
Soliris
Alexion
Xyrem
Jazz Pharmaceuticals
Flag link:

Pages